Understanding Current Trends and Advances in Transarterial Radioembolization Dosimetry
Authors:
- Shamar YoungShamar Young
- Kiyon Naser-TavakolianKiyon Naser-Tavakolian
- Abin SajanAbin Sajan
- Stephen ReisStephen Reis
- Gregory WoodheadGregory Woodhead
- Tyler SandowTyler Sandow
- Juan GimenezJuan Gimenez
- Kirema Garcia-ReyesKirema Garcia-Reyes
- Zachary BermanZachary Berman
- Venkatesh P. KrishnasamyVenkatesh P. Krishnasamy
Open Access
- 23 December 2025
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 43
Abstract
Transarterial radioembolization (TARE) is an established therapy for primary and secondary hepatic malignancies. Outcomes depend heavily on dosimetry, which has evolved from empirical and body-surface-area methods to partition and voxel-based approaches. This review summarizes current evidence for advanced (personalized) dosimetry across tumor types, highlights emerging dose–response concepts, and outlines practical barriers and implementation strategies. A narrative review of peer-reviewed clinical studies and trials evaluating dosimetry in TARE, with emphasis on hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), metastatic colorectal cancer (mCRC), neuroendocrine tumor (NET), and breast cancer liver metastases, was performed with comparison of single-compartment medical internal radiation dosimetry method (MIRD), partition (multicompartment) methods, and voxel-based dosimetry methodologies. Personalized dosimetry improves outcomes in multiple tumor types. A randomized trial in HCC showed superior overall survival with partition-based dosing versus MIRD. In selective HCC treatments, voxel-derived metrics (e.g., D95) correlate with complete pathologic necrosis, suggesting benefit beyond mean dose targets. For iCCA, data associate higher tumor doses with better radiologic response, progression-free survival, and downstaging. In mCRC, voxel-based and threshold analyses link specific tumor and margin doses with metabolic/radiographic response and survival. Smaller series in NET and breast cancer indicate dose–response relationships using advanced dosimetry. Evidence supports broader adoption of advanced dosimetry in TARE. Emerging strategies that ensure adequate coverage of the “coldest” tumor regions and thoughtful particle-load planning may further optimize results. Standardized protocols, prospective validation, and scalable workflows are needed to accelerate implementation.Keywords
This publication has 52 references indexed in Scilit:
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheresEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Planning dosimetry for 90Y radioembolization with glass microspheres: Evaluating the fidelity of 99mTc‐MAA and partition model predictionsMedical Physics, 2020
- Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explantsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic CholangiocarcinomaJAMA Oncology, 2020
- The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposureEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancerJournal of Surgical Oncology, 2004